These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35706081)

  • 61. COVID-19 Outbreak in Daegu City, Korea and Response to COVID-19: How Have We Dealt and What Are the Lessons?
    Kim SW
    J Korean Med Sci; 2022 Dec; 37(50):e356. PubMed ID: 36573388
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak.
    Lee CM; Park SW; Lee E
    Infect Chemother; 2022 Jun; 54(2):258-265. PubMed ID: 35706081
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased
    Kim H; Jang YR; Lee JY; Ko JH; Lee JY; Cho S; Lee YD; Song J; Hyun M; Kim HA; Hwang S; Ryou S; Na YJ; Lee JY; Lee C; Lee NY; Shin S; Kwon KT; Kim JY; Peck KR
    Front Cell Infect Microbiol; 2023; 13():1192512. PubMed ID: 37256107
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study.
    Noh HJ; Song JH; Ham SY; Park Y; Won HK; Kim SJ; Chung KB; Kim CK; Ahn YM; Lee BJ; Kang HR
    Medicine (Baltimore); 2023 Nov; 102(45):e35987. PubMed ID: 37960790
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.
    Jang YR; Oh YJ; Kim JY
    Int J Infect Dis; 2023 May; 130():94-100. PubMed ID: 36623794
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study.
    Choi SJ; Park SW; Lee E
    Infect Chemother; 2022 Mar; 54(1):91-101. PubMed ID: 35384421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019.
    Streinu-Cercel A; Săndulescu O; Preotescu LL; Kim JY; Kim YS; Cheon S; Jang YR; Lee SJ; Kim SH; Chang I; Suh JH; Lee SG; Kim MR; Chung DR; Kim HN; Streinu-Cercel A; Eom JS
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac053. PubMed ID: 35295819
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
    O'Horo JC; Challener DW; Speicher L; Bosch W; Seville MT; Bierle DM; Ganesh R; Wilker CG; Arndt RF; Arndt LL; Tulledge-Scheitel SM; Hanson SN; Razonable RR
    Mayo Clin Proc; 2022 Feb; 97(2):327-332. PubMed ID: 35120695
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance.
    Chen J; Wang R; Gilby NB; Wei GW
    J Chem Inf Model; 2022 Jan; 62(2):412-422. PubMed ID: 34989238
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
    Dejnirattisai W; Shaw RH; Supasa P; Liu C; Stuart AS; Pollard AJ; Liu X; Lambe T; Crook D; Stuart DI; Mongkolsapaya J; Nguyen-Van-Tam JS; Snape MD; Screaton GR;
    Lancet; 2022 Jan; 399(10321):234-236. PubMed ID: 34942101
    [No Abstract]   [Full Text] [Related]  

  • 71. Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
    Lee JY; Lee JY; Ko JH; Hyun M; Kim HA; Cho S; Lee YD; Song J; Shin S; Peck KR
    Front Immunol; 2021; 12():772320. PubMed ID: 34899724
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection.
    Kim JY; Jang YR; Hong JH; Jung JG; Park JH; Streinu-Cercel A; Streinu-Cercel A; Săndulescu O; Lee SJ; Kim SH; Jung NH; Lee SG; Park JE; Kim MK; Jeon DB; Lee YJ; Kim BS; Lee YM; Kim YS
    Clin Ther; 2021 Oct; 43(10):1706-1727. PubMed ID: 34551869
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.
    Ryu DK; Kang B; Noh H; Woo SJ; Lee MH; Nuijten PM; Kim JI; Seo JM; Kim C; Kim M; Yang E; Lim G; Kim SG; Eo SK; Choi JA; Song M; Oh SS; Chung HY; Tijsma AS; van Baalen CA; Kwon KS; Lee SY
    Biochem Biophys Res Commun; 2021 Nov; 578():91-96. PubMed ID: 34547629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
    Twohig KA; Nyberg T; Zaidi A; Thelwall S; Sinnathamby MA; Aliabadi S; Seaman SR; Harris RJ; Hope R; Lopez-Bernal J; Gallagher E; Charlett A; De Angelis D; Presanis AM; Dabrera G;
    Lancet Infect Dis; 2022 Jan; 22(1):35-42. PubMed ID: 34461056
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.